Pharma News

Currently nasal spray flu vaccine that uses a live but weakened form of the virus is not recommended for those under two as it is thought to be too strong to be safe for kids, and too weak to be effective for the elderly. Johns Hopkins researchers have developed a method to modify the nasal spray flu vaccine to make it effective for those under two and above 49 - two groups for which the vaccine is not approved. The study published online in the journal Vaccine.

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced an exclusive channel collaboration (ECC) to pursue the development and commercialisation of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder.

BTG plc, an international specialist healthcare company bringing announces that Health Canada has issued a Notice of Compliance approving Varithena (polidocanol injectable foam) for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system, above and below the knee.

New research has found that drug used for treatment of liver disease can also be used in treating Parkinson disease. The findings were detailed in the journal Neurology.

The US Food and Drug Administration (FDA) has approved Aprecia Pharmaceuticals Company's Spritam (levetiracetam) for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalised tonic-clonic seizures in adults and children with epilepsy.

A mammal communication research conducted by the University of Sussex suggests that, like humans, horses use muscles underlying various facial features including their nostrils, lips and eyes to alter their facial expressions in a variety of social situations. The research is published in PLOS ONE.

The European Commission (EC) has approved under the European Union (EU) Merger Regulation the Pfizer Inc's pending acquisition of Hospira, Inc. The Commission's decision includes Pfizer’s commitment to divest certain assets.